These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 28396978)

  • 1. A Novel Strategy to Co-target Estrogen Receptor and Nuclear Factor κB Pathways with Hybrid Drugs for Breast Cancer Therapy.
    Kastrati I; Siklos MI; Brovkovych SD; Thatcher GRJ; Frasor J
    Horm Cancer; 2017 Jun; 8(3):135-142. PubMed ID: 28396978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The NFkappaB pathway and endocrine-resistant breast cancer.
    Zhou Y; Eppenberger-Castori S; Eppenberger U; Benz CC
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S37-46. PubMed ID: 16113098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic targeting in the estrogen receptor hormonal pathway.
    Katzenellenbogen BS; Frasor J
    Semin Oncol; 2004 Feb; 31(1 Suppl 3):28-38. PubMed ID: 15052541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on the Role of NFκB in Promoting Aggressive Phenotypes of Estrogen Receptor-Positive Breast Cancer.
    Smart E; Semina SE; Frasor J
    Endocrinology; 2020 Oct; 161(10):. PubMed ID: 32887995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel aspirin prodrug inhibits NFκB activity and breast cancer stem cell properties.
    Kastrati I; Litosh VA; Zhao S; Alvarez M; Thatcher GR; Frasor J
    BMC Cancer; 2015 Nov; 15():845. PubMed ID: 26530254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective pressure of endocrine therapy activates the integrated stress response through NFκB signaling in a subpopulation of ER positive breast cancer cells.
    Semina SE; Pal P; Kansara NS; Huggins RJ; Alarid ET; Greene GL; Frasor J
    Breast Cancer Res; 2022 Mar; 24(1):19. PubMed ID: 35264224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoplasmic ERα and NFκB Promote Cell Survival in Mouse Mammary Cancer Cell Lines.
    Smart E; Alejo LH; Frasor J
    Horm Cancer; 2020 Apr; 11(2):76-86. PubMed ID: 32008217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear factor-ĸB plays a critical role in both intrinsic and acquired resistance against endocrine therapy in human breast cancer cells.
    Oida K; Matsuda A; Jung K; Xia Y; Jang H; Amagai Y; Ahn G; Nishikawa S; Ishizaka S; Jensen-Jarolim E; Matsuda H; Tanaka A
    Sci Rep; 2014 Feb; 4():4057. PubMed ID: 24531845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer.
    Iida M; Tsuboi K; Niwa T; Ishida T; Hayashi SI
    Breast Cancer; 2019 May; 26(3):272-281. PubMed ID: 30328006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story.
    McDaniel RE; Maximov PY; Jordan VC
    Vitam Horm; 2013; 93():1-49. PubMed ID: 23810002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer.
    Zhou Y; Yau C; Gray JW; Chew K; Dairkee SH; Moore DH; Eppenberger U; Eppenberger-Castori S; Benz CC
    BMC Cancer; 2007 Apr; 7():59. PubMed ID: 17407600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
    Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
    J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dimethyl Fumarate Inhibits the Nuclear Factor κB Pathway in Breast Cancer Cells by Covalent Modification of p65 Protein.
    Kastrati I; Siklos MI; Calderon-Gierszal EL; El-Shennawy L; Georgieva G; Thayer EN; Thatcher GR; Frasor J
    J Biol Chem; 2016 Feb; 291(7):3639-47. PubMed ID: 26683377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecularly targeted endocrine therapies for breast cancer.
    Orlando L; Schiavone P; Fedele P; Calvani N; Nacci A; Rizzo P; Marino A; D'Amico M; Sponziello F; Mazzoni E; Cinefra M; Fazio N; Maiello E; Silvestris N; Colucci G; Cinieri S
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S67-71. PubMed ID: 21129614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptors as therapeutic targets in breast cancer.
    Ariazi EA; Ariazi JL; Cordera F; Jordan VC
    Curr Top Med Chem; 2006; 6(3):181-202. PubMed ID: 16515478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
    Massarweh S; Schiff R
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo.
    Liu H; Lee ES; Gajdos C; Pearce ST; Chen B; Osipo C; Loweth J; McKian K; De Los Reyes A; Wing L; Jordan VC
    J Natl Cancer Inst; 2003 Nov; 95(21):1586-97. PubMed ID: 14600091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance.
    Sengupta S; Jordan VC
    Adv Exp Med Biol; 2008; 630():206-19. PubMed ID: 18637493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NFκB affects estrogen receptor expression and activity in breast cancer through multiple mechanisms.
    Frasor J; El-Shennawy L; Stender JD; Kastrati I
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 3(0 3):235-9. PubMed ID: 25450861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
    Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.